Post-translation modification and clostridial neurotoxins
AssigneeAllergan, Inc.
InventorsLance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
Life of this patent
Estimating the term…
Abstract
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
Claims11
A botulinum neurotoxin comprising a structural modification, wherein the structural modification comprises at least one additional N-glycosylation site, wherein the botulinum neurotoxin can interfere with the functions of a neuron, and wherein the additional N-glycosylation site increases biological persistence of the botulinum neurotoxin relative to a naturally-occurring botulinum neurotoxin of the same serotype without the additional N-glycosylation site.
A botulinum neurotoxin comprising a proteolytic domain from the light chain of a clostridial neurotoxin and at least one additional N-glycosylation site, wherein the additional N-glycosylation site increases biological persistence of the modified botulinum neurotoxin relative to a naturally-occurring botulinum neurotoxin of the same serotype without the additional N-glycosylation site.
Dependencies are inferred from the claim text.